

# NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Updated on 4/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

## Newly Diagnosed Disease

Osteosarcoma (Pulmonary mets)

AOST2031

Osteosarcoma (High Grade)

AOST2032

Classical Hodgkin Lymphoma

AHOD2131

Invasive Breast Carcinoma  
(HR+/HER2-)

NRG-BR009 (OFSET)\*^

Germ Cell Tumors

AGCT1531

AGCT1532

Precursor B-Lymphoblastic Leukemia  
(B-Cell ALL)

A041501\*

Adrenocortical Carcinoma

A092204

Low-grade Astrocytoma

A072301

## Recurrent Disease

Precursor B-Lymphoblastic Leukemia  
(B-Cell ALL)

AALL1821

Osteosarcoma (Pulmonary mets)

AOST2031

Precursor T-Lymphoblastic Leukemia/  
Lymphoma (T-Cell ALL/LBL) - MRD

EA9213

Adrenocortical Carcinoma

A092204

### Legend by Disease Types

Green =  
Osteosarcoma

Orange =  
Hodgkin  
Lymphoma

Purple =  
Breast

Yellow =  
Germ Cell  
Tumors

Blue =  
B-Cell  
ALL

Light Green =  
Adrenocortical  
Carcinoma

Light Gray =  
Low-grade  
Astrocytoma

Light Blue =  
T-Cell ALL /  
T-Cell LBL

Note: \* NRG-BR009 and A041501: Age 18 years and older; ^ NRG-BR009: COG is not directly participating.

## NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 4/15/2026)

Protocol Number	Phase	Protocol Title
<b>A041501</b>	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
<b>A072301</b>	III	Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
<b>A092204</b>	II	A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer
<b>AALL1821</b>	II	A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged $\geq 1$ to $< 31$ Years Old with First Relapse
<b>AGCT1531</b>	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
<b>AGCT1532</b>	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
<b>AHOD2131</b>	III	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
<b>AOST2031</b>	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
<b>AOST2032</b>	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
<b>EA9213</b>	II	A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
<b>NRG-BR009</b>	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score $\leq 25$ (OFSET)